OBJECTIVE: Heart transplant recipients undergo a number of invasive endomyocardial biopsies to screen for rejection. Serum assays of troponin T and/or I may provide a less invasive alternative. The purpose of this study was to evaluate troponin T and I as markers of cardiac transplant rejection. METHODS: We conducted a prospective analysis comparing troponin T and I levels to biopsy results in heart transplant recipients. Plasma was assayed for troponin T and I preoperatively, on the first 3 postoperative days, and with each subsequent biopsy. RESULTS: Twenty-nine patients entered the study. A total of 173 biopsies were performed at a mean follow-up of 129+/-9 days (range: 12-564 days). There were two rejection episodes (> or = grade 3), one in each of two patients. There were no significant relationships between troponin T or I and biopsy-proven rejection (> or = grade 3; P=0.59 and 0.54, respectively). There were also no correlations between troponin T or I levels and biopsy grade (P=0.40 and 0.92, respectively). Troponin T and I levels peaked on postoperative day 1 and fell to baseline over long-term follow-up with no peak in serum markers associated with rejection episodes. Donor ischemic time was significantly correlated to troponin T on postoperative days 1-3 (r=0.58, P=0.005; r=0.61, P=0.004; and r=0.61, P=0.003, respectively). CONCLUSIONS: Troponin T and I are not useful indicators of cardiac rejection, but do correlate with donor heart ischemic injury.
OBJECTIVE: Heart transplant recipients undergo a number of invasive endomyocardial biopsies to screen for rejection. Serum assays of troponin T and/or I may provide a less invasive alternative. The purpose of this study was to evaluate troponin T and I as markers of cardiac transplant rejection. METHODS: We conducted a prospective analysis comparing troponin T and I levels to biopsy results in heart transplant recipients. Plasma was assayed for troponin T and I preoperatively, on the first 3 postoperative days, and with each subsequent biopsy. RESULTS: Twenty-nine patients entered the study. A total of 173 biopsies were performed at a mean follow-up of 129+/-9 days (range: 12-564 days). There were two rejection episodes (> or = grade 3), one in each of two patients. There were no significant relationships between troponin T or I and biopsy-proven rejection (> or = grade 3; P=0.59 and 0.54, respectively). There were also no correlations between troponin T or I levels and biopsy grade (P=0.40 and 0.92, respectively). Troponin T and I levels peaked on postoperative day 1 and fell to baseline over long-term follow-up with no peak in serum markers associated with rejection episodes. Donorischemic time was significantly correlated to troponin T on postoperative days 1-3 (r=0.58, P=0.005; r=0.61, P=0.004; and r=0.61, P=0.003, respectively). CONCLUSIONS: Troponin T and I are not useful indicators of cardiac rejection, but do correlate with donorheart ischemic injury.
Authors: Zhengyang Liu; Luke A Perry; Jahan C Penny-Dimri; Michael Handscombe; Isabella Overmars; Mark Plummer; Reny Segal; Julian A Smith Journal: Transpl Int Date: 2022-06-08 Impact factor: 3.842
Authors: Qi-Fang Huang; Sander Trenson; Zhen-Yu Zhang; Jan Van Keer; Lucas N L Van Aelst; Wen-Yi Yang; Esther Nkuipou-Kenfack; Lutgarde Thijs; Fang-Fei Wei; Blerim Mujaj; Agnieszka Ciarka; Walter Droogné; Johan Vanhaecke; Stefan Janssens; Johan Van Cleemput; Harald Mischak; Jan A Staessen Journal: Transplant Direct Date: 2018-04-23
Authors: Estefanía Tarazón; Carolina Gil-Cayuela; María García Manzanares; Marta Roca; Francisca Lago; José Ramón González-Juanatey; Elena Sánchez-Lacuesta; Luis Martínez-Dolz; Manuel Portolés; Esther Roselló-Lletí Journal: Sci Rep Date: 2019-09-25 Impact factor: 4.379